A ground-breaking Canada-wide clinical trial led by Dr. Katherine Borden, at the Institute for Research in Immunology and Cancer (IRIC) of the Universit de Montral, has shown that a common anti-viral drug, ribavirin, can be beneficial in the treatment of cancer patients. Published in the journal Blood (First Edition), the study demonstrates that ribavirin suppresses the activities of the eIF4E gene in patients. This gene is dysregulated in 30 percent of cancers including breast, prostate, head and neck, colon and stomach cancer.
A study has suggested using aspirin could cut the risk of developing a type of stomach cancer by up to a third.
The British Journal of Cancer study looked at over 300,000 people.
The April issue of the journal Cancer Prevention Research published the results of a trial conducted by scientists at Tokyo University of Science, the University of Tsukuba in Japan, and Johns Hopkins University which determined that the isothiocyanate sulforaphane, a compound that occurs in high amounts in broccoli and its sprouts, helps suppress infection by Helicobacter pylori (H. pylori), the bacteria responsible for stomach ulcers and many cases of stomach cancer. The trial is the first to demonstrate an effect for broccoli against H. pylori in humans.
It is a cancer of the cells which form the structure of the stomach and intestine, not a cancer of the linings of the organ itself (that would be a carcinoma).
Primary carcinoma of the peritoneum is a rare type of disease and develops in the peritoneum. Peritoneum is the membrane that lines the abdominal cavity, fixes and covers all the organs in the abdominal cavity (e.g., intestine, liver and stomach).